Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Healthcare Professionals Reminded of the Risks of Accidental Exposure to Fentanyl Patches
The manufacturers of fentanyl patches (Durogesic Dtrans, Fencino, Fentalis, Matrifen, Mezolar, Mylafent, Opiodur, Osmanil, Tilofyl, Victanyl) have written to healthcare professionals to remind them about the potential risk of life-threatening harm from accidental exposure to the patches. Cases of accidental exposure continue to be reported, many involving children, and can occur if a patch is swallowed or transferred to another individual. To reduce this risk, patients and carers are advised as follows: • Choose the patch application site carefully (see instructions in the patient information leaflet). • Check the adhesion of the patch once applied, especially the edges. • Fold the used patch as soon as it is removed so that the adhesive side of the patch sticks firmly to itself and dispose of the folded patch safely. • If a patch is transferred to another person, remove it immediately and seek medical advice. • If a patch is swallowed, seek medical help immediately. For more information please visit: http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con428394.pdf
Learn More

Healthcare Professionals Advised About Safety Concerns with Vibativ
Clinigen has written to healthcare professionals to advise them about important safety concerns associated with the use of Vibativ (telavancin) and how to manage these in order to minimise risk to the patient. Vibativ contains the medication telavancin and is a new antibiotic for the treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) when alternative treatments are not appropriate or have failed. Vibativ should not be used in the treatment of complicated skin or soft tissue infections, or other non-approved indications, because the risks are thought to outweigh the benefits. All patients prescribed this antibiotic should have their kidney function monitored daily for at least the first three to five days of therapy and every 48-72 hours thereafter and it should not be prescribed in patients with severely impaired kidney function. Vibativ should be used with caution in patients who are at risk of an abnormal heart rhythm and it should not be used during pregnancy. For more information please visit: http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con428392.pdf
Learn More

Date Published Title Medicine Source
2014-07-02 Healthcare Professionals Reminded of the Risks of Accidental Exposure to Fentanyl Patches Fentanyl MHRA
2014-07-02 Healthcare Professionals Advised About Safety Concerns with Vibativ MHRA
2014-06-12 MHRA Advises Users to Following Instructions for Accu-Chek Blood Glucose Meters Insulin Aspart MHRA
2014-06-06 Healthcare Professionals Advised of Restrictions in Use of Domperidone Domperidone MHRA
2014-06-06 Healthcare Professionals Advised of Strengthened Warnings for Use of Adrenaline Pens Primatene MHRA
2014-06-06 Healthcare Professionals Given Latest Summary of Benefits and Risks of Statins Simvastatin MHRA
2014-06-06 Healthcare Professionals Advised that Zolpidem Impairs Driving Ability Next Day Zolpidem MHRA
2014-03-27 European Medicines Agency Recommends Restricting Strontium Use Because of Heart Disease Risk Strontium Ranelate EMEA
2014-03-26 New Pipette Design Launched for Cosopt Preservative-Free Eye Drops Dorzolamide Hydrochloride with Timolol Maleate MHRA
2014-03-26 Healthcare Professionals Advised to Restrict Use of Methysergide Methysergide MHRA
2014-03-26 Healthcare Professionals Warned that St John’s Wort Reduces Effectiveness of Contraceptives St. John's Wort MHRA
2014-03-26 Healthcare Professionals Warned that St John’s Wort Reduces Effectiveness of Contraceptives Desogestrel with Ethinylestradiol MHRA
2014-03-26 Healthcare Professionals Warned that Orlistat May Reduce Absorption of Antiretroviral HIV Medicines Orlistat MHRA
2014-03-26 Healthcare Professionals Warned that Orlistat May Reduce Absorption of Antiretroviral HIV Medicines Indinavir MHRA
2014-02-28 Healthcare Professionals Advised that Latest Review of Evidence Concludes Blood Clot Risk is Low With Combined Hormonal Contraceptives But Variable Between Products Nuvaring MHRA
2014-02-28 Healthcare Professionals Advised to Perform Genetic Test Before Starting Erbitux Treatment Cetuximab MHRA
2014-02-25 Healthcare Professionals Advised of Potential Supply Problems of Enbrel Injections Etanercept MHRA
2014-02-21 Cosopt Preservative-Free Eye Drops Recalled Over Container Problems Dorzolamide Hydrochloride with Timolol Maleate MHRA
2014-01-31 Healthcare Professionals Advised that the Increlex Shortage is Resolved Manufacturer
2014-01-31 Healthcare Professionals Advised to Screen Patients for Hepatitis B Before Treatment with Arzerra Manufacturer